GW Pharma scores another PhIII win for its cannabinoid in rare form of epilepsy
GW Pharmaceuticals can now boast about its fifth straight successful Phase III trial for its cannabinoid drug Epidiolex.
Researchers for the biotech said Monday evening that the drug hit the primary endpoint on both doses tested, with seizure reductions of 48.6% and 47.5% from baseline for patients suffering from tuberous sclerosis complex — another rare form of childhood epilepsy — compared to 26.5% for placebo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
